<html> <body> <H2> <FONT COLOR=A70716 SIZE=-1> </FONT> BARD1 Induces BRCA1 Intranuclear Foci Formation by Increasing RING-dependent BRCA1 Nuclear Import and Inhibiting BRCA1 Nuclear Export<A HREF="#FN150"><SUP>*</SUP></A> <BR> </H2> <STRONG> <NOWRAP> Megan Fabbro,<WBR> Jose A. Rodriguez<A HREF="#FN152"><SUP><IMG SRC="/math/12pt/normal/link/Dagger.gif" ALIGN=BOTTOM ALT="Dagger" BORDER=0></SUP></A>,<WBR> Richard Baer<SUP>&#167;</SUP>, and<WBR> Beric R. Henderson<A HREF="#FN154"><SUP>&#182;</SUP></A> </NOWRAP> </STRONG> <P> From the Westmead Institute for Cancer Research, University of Sydney, Westmead Millennium Institute at Westmead Hospital, Westmead, 2145,&nbsp;New South Wales, Australia and the <SUP>&#167;</SUP>&nbsp;Institute of Cancer Genetics, Department of Pathology, Columbia University College of Physicians and Surgeons, New York, New York 10032 <P> Received for publication, January 24,&nbsp;2002, and in revised form, March 21,&nbsp;2002 <P> <a name = "Abstract"><!-- comment for mosaic --></a> <A NAME="Abstract"><!-- null --></A> <TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0> <TR> <TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD> <TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;ABSTRACT</FONT></TH> </TR> </TABLE> <TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R> <TH ALIGN=LEFT> <FONT SIZE=-1> <A HREF="#Top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">TOP</A> <BR><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=46 4C53>ABSTRACT</FONT> <BR> <A HREF="#Introduction"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">INTRODUCTION</A> <BR> <A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">EXPERIMENTAL PROCEDURES</A> <BR> <A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">RESULTS</A> <BR> <A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">DISCUSSION</A> <BR> <A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">REFERENCES</A> </FONT></TH> </TR></TABLE> <P>BRCA1 is a tumor suppressor with several important nuclear functions. BRCA1 has no known cytoplasmic functions. We show here<SUP> </SUP>that the two previously identified nuclear localization signals<SUP> </SUP>(NLSs) are insufficient for nuclear localization of BRCA1 due<SUP> </SUP>to the opposing action of an NH<SUB>2</SUB>-terminal nuclear export signal.<SUP> </SUP>In transfected breast cancer cells, BRCA1 nuclear localization<SUP> </SUP>requires both the NLSs and NH<SUB>2</SUB>-terminal RING domain region; mutating<SUP> </SUP>either of these sequences shifts BRCA1 to the cytoplasm. The BRCA1<SUP> </SUP>RING element mediates nuclear import via association with BARD1,<SUP> </SUP>and this is not affected by cancer-associated RING mutations.<SUP> </SUP>Moreover, BARD1 directly masks the BRCA1 nuclear export signal,<SUP> </SUP>and the resulting block to nuclear export is requisite for efficient<SUP> </SUP>import and nuclear localization of ectopic and endogenous BRCA1.<SUP> </SUP>Our results explain why BRCA1 exon 11&nbsp;splice variants, which lack<SUP> </SUP>the NLSs but retain the RING domain, are frequently detected in<SUP> </SUP>the nucleus and in nuclear foci <I>in vivo</I>. In fact, co-expression<SUP> </SUP>of BARD1 promoted formation of DNA damage-induced nuclear foci<SUP> </SUP>comprising ectopic wild-type or NLS-deficient BRCA1, implicating<SUP> </SUP>BARD1 in nuclear targeting of BRCA1 for DNA repair. Our identification<SUP> </SUP>of BARD1 as a BRCA1 nuclear chaperone has regulatory implications<SUP> </SUP>for its reported effects on BRCA1 protein stability, ubiquitin<SUP> </SUP>ligase activity, and DNA<SUP> </SUP>repair. <BR><BR CLEAR=ALL> <TXT> <A NAME="SEC0"><!-- comment for mosaic --></A> <A NAME="Introduction"><!-- null --></A> <TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0> <TR> <TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD> <TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;INTRODUCTION</FONT></TH> </TR> </TABLE> <TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R> <TH ALIGN=LEFT> <FONT SIZE=-1> <A HREF="#Top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">TOP</A> <BR> <A HREF="#Abstract"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">ABSTRACT</A> <BR><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=46 4C53>INTRODUCTION</FONT> <BR> <A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">EXPERIMENTAL PROCEDURES</A> <BR> <A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">RESULTS</A> <BR> <A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">DISCUSSION</A> <BR> <A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">REFERENCES</A> </FONT></TH> </TR></TABLE> <P>The tumor suppressor, <I>BRCA1</I>, was the first susceptibility gene linked to breast and ovarian cancer (<A HREF="#B1">1</A>). Germ-line mutations<SUP> </SUP>of BRCA1 are found in ~50% of patients with inherited breast cancer<SUP> </SUP>and up to 90% of families with breast and ovarian cancer susceptibility<SUP> </SUP>(<A HREF="#B1">1</A>, <A HREF="#B2">2</A>). The role of BRCA1 as a tumor suppressor is not fully<SUP> </SUP>defined, although accumulated evidence suggests that BRCA1 plays<SUP> </SUP>a role in transcriptional regulation (<A HREF="#B3">3</A>), cell cycle control<SUP> </SUP>(<A HREF="#B4">4</A>, <A HREF="#B5">5</A>), and cell survival responses to DNA damage (<A HREF="#B6">6-8</A>). </P> <P><I>BRCA1</I> is a large gene of 24&nbsp;exons that encodes a 1,863-amino acid protein (<A HREF="#B1">1</A>). The BRCA1 protein contains several protein-interaction<SUP> </SUP>domains: an NH<SUB>2</SUB>-terminal RING domain common to many regulatory<SUP> </SUP>proteins (<A HREF="#B1">1</A>), two tandem copies of the BRCT (<U>BR</U>CA1 <U>c</U>arboxyl<SUP> </SUP><U>t</U>erminus) motif at the COOH terminus (<A HREF="#B9">9</A>), and both nuclear<SUP> </SUP>import (<A HREF="#B10">10</A>, <A HREF="#B11">11</A>) and export signals (<A HREF="#B12">12</A>). The BRCT domain<SUP> </SUP>is found in a variety of proteins, including 53BP1, RAD9, RAD4,<SUP> </SUP><I>Crb2</I>, and RAP1, all of which are associated with cell cycle regulation<SUP> </SUP>and DNA repair (<A HREF="#B13">13</A>). The BRCT motifs of BRCA1 appear to be critical<SUP> </SUP>for its transcription activation function (<A HREF="#B3">3</A>, <A HREF="#B14">14</A>), and cancer<SUP> </SUP>mutations in this COOH-terminal region impair transcriptional<SUP> </SUP>activity (<A HREF="#B3">3</A>, <A HREF="#B15">15</A>). This is likely due to altered association<SUP> </SUP>with specific proteins, such as the RNA polymerase II holoenzyme,<SUP> </SUP>which normally interacts with the COOH terminus of BRCA1 (<A HREF="#B16">16</A>). </P> <P>The NH<SUB>2</SUB>-terminal RING domain of BRCA1 mediates association with proteins including BARD1 (<A HREF="#B17">17</A>) and BAP1 (<A HREF="#B18">18</A>). BARD1 is<SUP> </SUP>similar in primary structure to BRCA1, in that it also contains<SUP> </SUP>an NH<SUB>2</SUB>-terminal RING finger and two COOH-terminal BRCT domains<SUP> </SUP>(<A HREF="#B17">17</A>). BRCA1 and BARD1 interact via their RING domains (<A HREF="#B19">19</A>),<SUP> </SUP>and co-localize in discrete nuclear dots during S-phase of the<SUP> </SUP>cell cycle (<A HREF="#B20">20</A>), and in DNA damage-inducible nuclear foci thought<SUP> </SUP>to be involved in DNA repair/replication (<A HREF="#B6">6</A>). The BRCA1-BARD1<SUP> </SUP>complex has recently been shown to exhibit ubiquitin ligase activity<SUP> </SUP>that is disrupted by BRCA1 breast cancer-associated RING finger<SUP> </SUP>mutations (<A HREF="#B21">21-23</A>), implicating BARD1 as a regulator of BRCA1 function<SUP> </SUP>and tumor suppressor<SUP> </SUP>activity. </P> <P>In recent years, the subcellular localization of BRCA1 has been controversial (<A HREF="#B24">24-26</A>), due in part to variable specificity<SUP> </SUP>of BRCA1 antibodies. BRCA1 is now generally regarded as a nuclear<SUP> </SUP>protein (<A HREF="#B4">4</A>, <A HREF="#B26">26</A>) that accumulates in discrete nuclear foci<SUP> </SUP>in epithelial cell lines (<A HREF="#B6">6</A>, <A HREF="#B25">25</A>, <A HREF="#B26">26</A>), in particular those<SUP> </SUP>derived from breast tumors. The known tumor suppressor functions<SUP> </SUP>of BRCA1 also occur most in the nucleus (<A HREF="#B15">15</A>, <A HREF="#B27">27</A>). BRCA1 contains<SUP> </SUP>two SV40-like nuclear localization signals (NLSs<SUP>1</SUP>; <SUP>503</SUP>KRKRRP<SUP>508</SUP> and <SUP>606</SUP>PKKNRLRRKS<SUP>615</SUP>) that facilitate nuclear import by the importin <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">/<IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta "> receptor<SUP> </SUP>pathway (<A HREF="#B10">10</A>, <A HREF="#B11">11</A>). Although BRCA1 locates predominantly to<SUP> </SUP>the nucleus, it contains an NH<SUB>2</SUB>-terminal nuclear export signal<SUP> </SUP>(NES</A>) and can shuttle between nucleus and cytoplasm (<A HREF="#B12">12</A>). The<SUP> </SUP>BRCA1 splice variants, BRCA1 <IMG SRC="/math/12pt/normal/Delta.gif" ALIGN=BOTTOM ALT="Delta ">11b (<A HREF="#B28">28</A>) and BRCA1 <IMG SRC="/math/12pt/normal/Delta.gif" ALIGN=BOTTOM ALT="Delta ">672-4095 (<A HREF="#B11">11</A>),<SUP> </SUP>are highly expressed in many cells, and yet even though they lack<SUP> </SUP>exon 11&nbsp;which contains the two nuclear localization signals (<A HREF="#B28">28</A>),<SUP> </SUP>several groups have detected BRCA1 <IMG SRC="/math/12pt/normal/Delta.gif" ALIGN=BOTTOM ALT="Delta ">11b in the nucleus (<A HREF="#B28">28-30</A>).<SUP> </SUP>In particular, Huber <I>et al.</I> (<A HREF="#B30">30</A>) examined localization of the<SUP> </SUP>endogenous BRCA1 exon 11&nbsp;splice variant expressed in mouse embryo<SUP> </SUP>fibroblasts, and showed that this NLS-deficient protein enters<SUP> </SUP>the nucleus and assembles into DNA damage-inducible nuclear foci<SUP> </SUP>almost identical to that of full-length BRCA1. Given the importance<SUP> </SUP>of nuclear targeting for BRCA1 function, we have searched for<SUP> </SUP>alternative BRCA1 nuclear import pathways that act independent<SUP> </SUP>of its nuclear import<SUP> </SUP>signals. </P> <P>In this study, we show that transiently expressed BRCA1 splice variant and full-length forms of BRCA1 that lack an NLS</A> can<SUP> </SUP>enter the nucleus. This novel NLS-independent import process is<SUP> </SUP>dependent on the NH<SUB>2</SUB>-terminal RING domain region of BRCA1, a sequence<SUP> </SUP>well conserved in all BRCA1 splice variants. The RING-mediated<SUP> </SUP>import pathway is facilitated by the BRCA1-binding partner, BARD1.<SUP> </SUP>BARD1 not only translocates BRCA1 into the nucleus, but retains<SUP> </SUP>it there by masking its nuclear export signal, which lies buried<SUP> </SUP>within the BRCA1-BARD1 binding interface (<A HREF="#B31">31</A>). Our findings<SUP> </SUP>identify a key "chaperone" role for BARD1 in promoting BRCA1 nuclear<SUP> </SUP>entry and formation of DNA damage-inducible BRCA1 nuclear foci,<SUP> </SUP>and provide an explanation for the DNA damage response observed<SUP> </SUP>for cellular BRCA1 splice variants (<A HREF="#B30">30</A>), which contains a RING<SUP> </SUP>domain but no NLS</A> sequence. Our results also help resolve much<SUP> </SUP>of the controversy concerning BRCA1 subcellular localization,<SUP> </SUP>and shed light on a new and unexpected regulatory role of<SUP> </SUP>BARD1. <BR><BR CLEAR=ALL> <A NAME="SEC1"><!-- null --></A> <TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0> <TR> <TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD> <TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;EXPERIMENTAL PROCEDURES</FONT></TH> </TR> </TABLE> <TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R> <TH ALIGN=LEFT> <FONT SIZE=-1> <A HREF="#Top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">TOP</A> <BR> <A HREF="#Abstract"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">ABSTRACT</A> <BR> <A HREF="#Introduction"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">INTRODUCTION</A> <BR><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=46 4C53>EXPERIMENTAL PROCEDURES</FONT> <BR> <A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">RESULTS</A> <BR> <A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">DISCUSSION</A> <BR> <A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">REFERENCES</A> </FONT></TH> </TR></TABLE> <P ALIGN=CENTER><B>Cell Culture and Transfection</B> </P> <P>MCF-7 and T47D human breast cancer cells, and HBL100 immortalized human breast epithelial cells, were maintained in Dulbecco's<SUP> </SUP>modified Eagle's media supplemented with 10% fetal calf serum.<SUP> </SUP>All cells were grown at 37&nbsp;&#176;C in a humidified 5% CO<SUB>2</SUB> atmosphere.<SUP> </SUP>Cells were seeded onto sterile glass coverslips and transfected<SUP> </SUP>at 50-60% confluency with 1&nbsp;to 2&nbsp;&#181;g of plasmid DNA using LipofectAMINE<SUP> </SUP>Reagent (Invitrogen) according to the manufacturer's instructions.<SUP> </SUP>At 6&nbsp;h post-transfection, the transfection mixture was removed<SUP> </SUP>and replaced with Dulbecco's modified Eagle's media containing<SUP> </SUP>10% fetal calf serum. Cells were fixed and processed 30&nbsp;h post-transfection<SUP> </SUP>for fluorescence microscopy. When required, transfected cells<SUP> </SUP>were treated with leptomycin B at a final concentration of 6&nbsp;ng/ml<SUP> </SUP>for 4&nbsp;h prior to<SUP> </SUP>fixation. </P> <P ALIGN=CENTER><B>Plasmid Construction</B> </P> <P>Construction of the expression vectors pF-BRCA1, pYFP-BRCA1, pYFP-BRCA1(<IMG SRC="/math/12pt/normal/Delta.gif" ALIGN=BOTTOM ALT="Delta ">306-1312), pBRCA1-NESm, pBRCA1(<IMG SRC="/math/12pt/normal/Delta.gif" ALIGN=BOTTOM ALT="Delta ">1-70), and pYFP-CRM1<SUP> </SUP>were described previously (<A HREF="#B12">12</A>). The YFP</A> cDNA was excised as<SUP> </SUP>a <I>Not</I>I fragment from the above YFP-fusion constructs to create<SUP> </SUP>untagged pBRCA1(<IMG SRC="/math/12pt/normal/Delta.gif" ALIGN=BOTTOM ALT="Delta ">306-1312), pBRCA1(<IMG SRC="/math/12pt/normal/Delta.gif" ALIGN=BOTTOM ALT="Delta ">1-70), and pBRCA1-NESm plasmids.<SUP> </SUP>To create pF-CRM1, the CRM1 cDNA was excised from the CRM1.pET16b<SUP> </SUP>plasmid (provided by Dr. M.&nbsp;Yoshida, Tokyo) and inserted into<SUP> </SUP>the pFlag-CMV2 vector (Eastman Kodak Co.) as a <I>Kpn</I>I/<I>Bam</I>HI fragment.<SUP> </SUP>We used a PCR strategy to introduce site-directed mutations into<SUP> </SUP>the two nuclear localization signals of BRCA1<SUP> </SUP>cDNA. </P> <P><I>Mutation of NLS</A>-(503-508)--</I> The first PCR introduced mutations into NLS1 in wild-type BRCA1 using primers MF1 (forward) and MF2 (reverse; codons in bold<SUP> </SUP>represent the amino acids Lys<SUP>503</SUP>, Arg<SUP>504</SUP>, Lys<SUP>505</SUP>, and Arg<SUP>506</SUP> that were mutated to alanine). The primer sequences are shown<SUP> </SUP>in Table <a href="#TI">I</a>. A second overlapping PCR product was generated using<SUP> </SUP>primers MF6 (forward) and MF7 (reverse). The two DNA products<SUP> </SUP>(MF1/2 and MF6/7) were then annealed and amplified with primers<SUP> </SUP>MF1 and MF7, and the resulting PCR fragment was gel purified and<SUP> </SUP>inserted into wild-type BRCA1 as an <I>Afl</I>II/<I>Kpn</I>I fragment, to generate<SUP> </SUP>pBRCA1-NLSm1. <P><CENTER> <TABLE BORDER WIDTH="95%" CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD> <TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1><TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>